Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 1/2009

01-02-2009 | PRECLINICAL STUDIES

Effect of morin on tissue lipid peroxidation and antioxidant status in 1, 2-dimethylhydrazine induced experimental colon carcinogenesis

Authors: Vennila Sreedharan, Karthik Kumar Venkatachalam, Nalini Namasivayam

Published in: Investigational New Drugs | Issue 1/2009

Login to get access

Summary

Colon cancer is the third most malignant neoplasm in the world and it remains today an important cause of death, especially in western countries. In this study, we have evaluated the chemopreventive efficacy of morin on tissue lipid peroxidation and antioxidant status, which are used as biomarkers in 1,2-dimethylhydrazine-induced colon carcinogenesis in a rat model. Male Wistar rats were divided into four groups and received high fat diet. Group 1 served as control, groups 2 and 4 were given a daily treatment of morin (50 mg/kg body weight) orally, everyday for a total period of 30 weeks. Groups 3 and 4 were given weekly subcutaneous injections of DMH at a dose of 20 mg/kg body weight in the groin for 15 weeks. Animals were sacrificed at the end of 30 weeks. The liver, intestine, colon and caecum from different groups were subjected to histopathological studies, determination of lipid peroxidation and antioxidant status. Our results showed decreased levels of liver enzymic and non-enzymic antioxidants and increased levels of lipid peroxidation (LPO) products such as tissue thiobarbituricacid substances (TBARS), lipid hydroperoxides (LOOH) and conjugated dienes (CD) in DMH treated rats, which were significantly (P < 0.05) reversed on morin supplementation. Moreover, intestinal, colonic and caecal TBARS, LOOH, CD and also the antioxidants superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase (GST), glutathione peroxidase (GPx), glutathione reductase (GR) and reduced glutathione (GSH) were significantly diminished in DMH treated rats, which were significantly (P < 0.05) elevated on simultaneous morin supplementation. Moreover, enhanced activity of intestinal, colonic and caecal ascorbic acid and α-tocopherol levels were also observed in DMH alone treated rats, which were significantly (P < 0.05) reduced on morin supplementation. These results indicate that morin could exert a significant chemopreventive effect on colon carcinogenesis induced by DMH.
Literature
1.
World Health Organization (WHO) (1997) The world health report. WHO, Geneva
2.
Weisburger JH (1991) Nutritional approach to cancer prevention with emphasis on vitamins, antioxidants and carotenoids. Am J Clin Nutr 53:226S–237SPubMed
3.
Ohno K, Narnshima S, Takeuchi S, Itoh K, Itoh T, Hioki K, Nomura T (2001) Effect of bacterial metabolism in the intestine on colorectal tumors induced by 1,2-dimethylhydrazine in transgenic mice harboring human prototype C-Ha-ras genes. J Exp Clin Can Res 20:51–56
4.
Fiala E (1975) Investigations into the metabolism and mode of action of the colon carcinogen 1,2-dimethylhydrazine. Cancer 36:2407–2412PubMedCrossRef
5.
Wiseman H, Halliwell B (1996) Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J 313:17–29PubMed
6.
DiGiovanni J (1990) Inhibition of chemical carcinogenesis, chemical carcinogenesis and mutagenisis II. Springer, Berlin, pp 159–202
7.
Middleton E, Kandaswami C (1994) The impact of plant flavonoids on mammalian biology:implications for immunity, inflammation and cancer. The flavonoids: advances in research. Chapman and Hall, London, pp 619–652
8.
Hollman PCH, Katan MB (1997) Absorption, metabolism and health effects of dietary flavonoids in man. Biomed Pharmacother 51:305–310PubMedCrossRef
9.
Kandaswami C, Middleton E (1994) Free radical scavenging and antioxidant activity of plant flavonoids. Adv Exp Med Biol 366:351–376PubMed
10.
Fraga CG, Martino VS, Ferraro GE, Coussio JD, Boveris A (1987) Flavonoids as antioxidants evaluated by in vitro and in situ liver chemiluminescence. Biochem Pharmacol 36:717–720PubMedCrossRef
11.
Sengottuvelan M, Viswanathan P, Nalini N (2006) Chemopreventive effect of trans-resveratrol—a phytoalexin against colonic aberrant crypt foci and cell proliferation in 1,2-dimethylhydrazine induced colon carcinogenesis. Carcinogenesis 5:1038–1046
12.
Kamaleeswari M, Nalini N (2006) Dose response efficacy of Caraway (Carum carvi L.) on tissue lipid peroxidation and antioxidant profile in rat colon carcinogenesis. J Pharm Pharmacol 58:1121–1130PubMedCrossRef
13.
Hanasaki Y, Ogawaa S, Fukui S (1994) The correlation between active oxygen scavenging and antioxidative effects of flavonoids. Free Radic Biol Med 16:845–850PubMedCrossRef
14.
Francis AR, Shetty TK, Bhattacharya RK (1989) Modifying role of dietary factors on the mutagenicity of aflatoxin B1: in vitro effect of plant flavonoids. Mutat Res 222:303–401
15.
Denda A, Ura H, Tsujiuchi T, Tsutsumi M, Eimoto H, Takashima Y, Kitazawa S, Kinugasa T, Konishi Y (1989) Possible involvement of arachidonic acid metabolism in phenobarbital promotion of hepatocarcinogenesis. Carcinogenesis 10:1929–1935PubMedCrossRef
16.
Yugarani T, Tan BKH, Teh M, Das NP (1992) Effects of polyphenolic natural products on the lipid profile of rats fed high fat diet. Lipids 27:181–186PubMedCrossRef
17.
Ohkawa H, Ohisi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358PubMedCrossRef
18.
Rao KS, Recknagel RO (1968) Early onset of lipid peroxidation in rat liver after carbon tetrachloride administration. Exp Mol Pathol 9:271–278PubMedCrossRef
19.
Jiang ZY, Hunt JV, Wolff SP (1992) Ferrous ion oxidation in the presence of xylenol orange for detection of lipid hydroperoxides in low density lipoprotein. Anal Biochem 202:384–389PubMedCrossRef
20.
Kakkar PS, Das B, Viswanathan PN (1984) A modified spectrophotometric assay of superoxide dismutase. Ind J Biochem Biophys 21:130–132
21.
22.
23.
Carlberg I, Mannervik B (1985) Glutathione reductase. Methods in enzymology 7. Academic, New York, pp 484–490
24.
Rotruck JT, Pope AL, Ganther HE, Swanson AB, Hafeman DG, Hoekstra WG (1973) Selenium: biochemical role as a component of glutathione peroxidase. Science 179:588–590PubMedCrossRef
25.
Habig WH, Pabst MJ, Jakoby WB (1974) Glutathione-S-transferases, the first enzymatic step in mercapturic acid formation. J Biol Chem 249:7130–7139PubMed
26.
Roe JM, Kuether CA (1943) Detection of ascorbic acid in whole blood, and urine through 2,4-DNPH derivative of dehydroascorbic acid. J Biol Chem 147:399–407
27.
Baker H, Frank O, DeAngelis B, Feingold S (1980) Plasma tocopherol in man at various times after ingesting free or acetylated tocopherol. Nutr Rep Int 21:531–536
28.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with Folin’s phenol reagent. J Biol Chem 193:265–275PubMed
29.
Cooper HK, Buecheler J, Kleihues P (1978) DNA alkylation in mice with genetically difference susceptibility to 1,2-dimethylhydrazine-induced colon carcinogenesis. Cancer Res 38:3063–3065PubMed
30.
Fiala ES (1977) Investigations into the metabolism and mode of action of the colon carcinogens 1,2-dimethylhydrazine and azoxymethane. Cancer 40:2436–2445PubMedCrossRef
31.
Das U (2002) A radical approach to cancer. Med Sci Monit 8:RA79–RA92PubMed
32.
Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 29:803–809CrossRef
33.
Wu TW, Zeng LH, Wu J, Fung KP (1994) Morin: a wood pigment that protects three types of human cells in the cardiovascular system against oxyradical damage. Biochem Pharmacol 47:1099–1103PubMedCrossRef
34.
Cholbi MR, Paya M, Alcaraz MJ (1991) Inhibitory effects of phenolic compounds on CCl4-induced microsomal lipid peroxidation. Experientia 47:195–199PubMedCrossRef
35.
Kenneth AC (2000) Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr Cancer 37:1–18CrossRef
36.
Bartoli GM, Galeotti T (1979) Growth—related lipid peroxidation in tumor microsomal membranes and mitochondria. Biochem Biophys Acta 574:537–541PubMed
37.
Byung Pal YU (1994) Cellular defenses against damage from reactive oxygen species. Physiol Rev 14:139–162
38.
Rajeshkumar NV, Kuttan R (2003) Modulation of carcinogenic response and antioxidant enzymes of rats administered with 1,2-dimethylhydrazine by Picroliv. Cancer Lett 191:137–143PubMedCrossRef
39.
Janssen AM, Bosman CB, Kruidenier L, Griffioxn G, Lamers CB, Van krieken JH, Van de Velde CJ, Verspaget HW (1999) Superoxide dismutases in the human colorectal cancer sequence. J Cancer Res Clin Oncol 125:327–335PubMedCrossRef
40.
Brigelius-Flohe R (1999) Tissue-specific functions of individual glutathione peroxidases. Free Radic Biol Med 27:951–965PubMedCrossRef
41.
Linder MC (1985) Nutrition and cancer prevention, nutritional biochemistry and metabolism with chemical applications. Elsevier, New York, pp 347–368
42.
Sies H (1986) Biochemistry of oxidative stress. Angewandte Chem 25:1058–1071CrossRef
43.
Navarro J, Obrador E, Carretero J, Petschen I, Avino J, Perez P, Estrela JM (1999) Changes in glutathione status and the antioxidant system in blood and in cancer cells associate with tumor growth in vivo. Free Radic Biol Med 26:410–418PubMedCrossRef
44.
Tanaka T, Kawabata K, Kakumoto M, Makita H, Ushida J, Honjo S, Hara A, Tsuda H, Mori H (1999) Modifying effects of a flavonoid morin on azoxymethane-induced large bowel tumorigenesis in rats. Carcinogenesis 20:1477–1484PubMedCrossRef
45.
Henson DE, Block G, Levine M (1991) Ascorbic acid; biologic functions and relation to cancer. J Natl Cancer Inst 83:547–550PubMedCrossRef
46.
Mehlhorn RJ, Sumida S, Packer L (1989) Tocopheroxyl radical persistence and tocopherol consumption in liposomes and in vitamin E-enriched rat liver mitochondria and microsomes. J Biol Chem 264:13448–13452PubMed
47.
Cheeseman KH, Burton GW, Ingold KU, Slater TF (1984) Lipid peroxidation and lipid antioxidants in normal and tumor cells. Toxicol Pathol 12:235–239PubMedCrossRef
Metadata
Title
Effect of morin on tissue lipid peroxidation and antioxidant status in 1, 2-dimethylhydrazine induced experimental colon carcinogenesis
Authors
Vennila Sreedharan
Karthik Kumar Venkatachalam
Nalini Namasivayam
Publication date
01-02-2009
Publisher
Springer US
Published in
Investigational New Drugs / Issue 1/2009
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-008-9136-1

Other articles of this Issue 1/2009

Investigational New Drugs 1/2009 Go to the issue

PRECLINICAL STUDIES

The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib

PRECLINICAL STUDIES

Brazilian marine sponge Polymastia janeirensis induces apoptotic cell death in human U138MG glioma cell line, but not in a normal cell culture

PHASE II STUDIES

A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer

PHASE I STUDIES

A phase I trial of PTK787/ZK222584 in combination with pemetrexed and cisplatin in patients with advanced solid tumors

PRECLINICAL STUDIES

Antitumor activity of a novel EGFR tyrosine kinase inhibitor against human lung carcinoma in vitro and in vivo

PHASE I STUDIES

A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits